Off-Label Anticancer Drugs Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2026 Off label is the unwarranted or non-approved use of the drug. Under three conditions a drug is offlabel. The conditions are • The measures needed to extend the consent were not made albeit implication of adequacy is applicable • The drug is ineffectual or ineffective • It falls in 'grey zone' information-based medicine in which top-level evidence of is tough to find even for the treatments which are fairly effective. For some reasons, these are more accurate in oncology when compared to other medical areas. Multiple across the board drugs are yet to receive the label for all the indications under which they can be effectively employed. The off-label usage of FDA-approved drugs is not regulated however; in many countries including the United State, it is legal. The usage of off-label drug use is more frequent in cancer treatment because multiple drugs are efficient in fighting against more than one cancer. A large study conducted by Kocs D, Fendrick AM in the US revealed that 33.2% of chemotherapy, including hormonal therapy, administered by oncologists was being used off-label. It is most common among cancer therapies due to limited availability of approved drugs for treatment. They are proven effective for many indications and in combination therapies when compared to monotherapy. Further, rising cancer prevalence among general population fuelled the growth of the market. Along with this, changing regulatory conditions to support manufacturers in the rapid advancement of technologies led to robust growth. Persistent demand for anti-neoplastic drugs in better management of cancer fuelled the demand for off-label drugs. It is legal in the US for off-label drug use and offers reimbursements for cancer treatment. Additionally, growing research activities to expand the disease indication fuelled the investments. All these factors led to the robust growth of the market during the forecast period. However, It's authorized for doctors to use off label drug but it's not legitimate for drug companies to promote off label drugs. Request a Sample Report @ https://www.futurewiseresearch.com/requestsample.aspx?id=206&page=requestsample Usage of off label drug can perplex reimbursement and coverage of health insurance which acts as a restraint for the growth of the market. Since the drug is not formally indicated for the treatment of the specific disease, the prescriber can end up paying its full price. Also, there's a slight chance that producing company might withdraw the drug from the market when it's no longer required which may hinder the prospects of the market. The global market is dominated by North America due to supportive regulatory policies and high adoption among physicians. North America is dominated by the US and it is expected to remain dominant same throughout the forecast period. It is followed by the European region and it is dominated by the UK, Germany, and France. European regulatory bodies restrict the off-label drug use but there is high adoption among the general physicians. It is followed by the Asia Pacific and Latin America regions are fast growing regions due to increasing adoption. They are expected accounts for 25% share of the global market. Rest of World accounts the small fraction of the global market and expected to remain the same throughout the forecast period. Off-Label Anticancer Drugs market players include Pfizer Inc, Roche Holding, Merck Co & Inc, Novartis AG, Sanofi S.A., Gilead, J&J and others. Off-Label Anticancer Drugs Restraints: • Perplexes reimbursement and coverage of health insurance. • Manufacturing company might withdraw the drug from the market when it's no longer required Purchase a Copy of this Premium Research Report & Ask for Discount: https://www.futurewiseresearch.com/request-sample.aspx?id=206&page=askfordiscount Off-Label Anticancer Drugs Market Segmentation By Indications • Lung Cancer • Breast Cancer • Prostate Cancer • Skin Cancer • Bladder Cancer • Others By End Users • Hospitals • Pharmacies By Region: • North America • Latin America • Europe • Asia Pacific • Rest of the World Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Global Off-Label Anticancer Drugs Market by Indications, by End-User, and by Region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies Table of Contents 1.1. Introduction 1.1.1.1. Scope and Objective 1.1.1.2. Assumptions and Acronyms 1.1.1.3. Forecast Factors 1.1.1.4. Research Methodology 1.2. Executive Summary 1.2.1.1. Industry Cluster Analysis 1.2.1.2. Competition Matrix 1.2.1.3. Strategies Recommendations 1.3. Market Definition 1.3.1.1. Report Scope (Inclusions & Exclusions) 1.3.1.2. Market Segmentation 1.4. Global Off-Label Anticancer Drugs Market Overview 1.4.1.1. Global Off-Label Anticancer Drugs Market Revenue (USD Mn) 1.5. Key Inclusions 1.5.1.1. Porter’s Five Force analysis 1.5.1.2. Market Dynamics 1.5.1.3. Industry Trends 1.5.1.4. Regulatory Guidelines 1.5.1.5. Opportunities in Off-Label Anticancer Drugs 1.6. Competition Dynamics 1.6.1.1. Company Share Analysis (2018) 1.6.1.2. Top 10 Product Pricing by Region 1.7. Global Off-Label Anticancer Drugs Market Revenue (USD Mn), 2018-2026 by Indication 1.7.1.1. Key Market Findings 1.7.1.2. Long Term ROI Segments 1.7.1.3. Revenue Opportunity Influencing Factors 1.7.1.4. Market Revenue (USD Mn) Assessment and Forecast by Indication, 2018-2026 1.7.1.4.1.1. Lung Cancer 1.7.1.4.1.2. Breast Cancer 1.7.1.4.1.3. Prostate Cancer 1.7.1.4.1.4. Skin Cancer 1.7.1.4.1.5. Bladder Cancer 1.7.1.4.1.6. Others 1.8. Global Off-Label Anticancer Drugs Market Revenue (USD Mn), 2018-2026 by End User 1.8.1.1. Key Market Findings 1.8.1.2. Long Term ROI Segments 1.8.1.3. Revenue Opportunity Influencing Factors 1.8.1.4. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 1.8.1.4.1.1. Hospitals 1.8.1.4.1.2. Pharmacies 1.9. Global Off-Label Anticancer Drugs Market Revenue (USD Mn), 2018-2026 by Region 1.9.1.1. Key Market Findings 1.9.1.2. Long Term ROI Segments 1.9.1.3. Revenue Opportunity Influencing Factors 1.9.1.4. Market Revenue (USD Mn) Assessment and Forecast by Region,2026 1.9.1.4.1.1. North America 1.9.1.4.1.2. Latin America 1.9.1.4.1.3. Europe 1.9.1.4.1.4. Asia Pacific 1.9.1.4.1.5. Rest of world 1.10. North America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 2018-2026 1.10.1.1. Key Market Findings 1.10.1.2. Long Term ROI Segments 1.10.1.3. Revenue Opportunity Influencing Factors 1.10.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026 1.10.1.4.1.1. US 1.10.1.4.1.2. Canada 1.10.1.5. Market Revenue (USD Mn) Assessment and Forecast by Indication, 2018-2026 1.10.1.5.1.1. Lung Cancer 1.10.1.5.1.2. Breast Cancer 1.10.1.5.1.3. Prostate Cancer 1.10.1.5.1.4. Skin Cancer 1.10.1.5.1.5. Bladder Cancer 1.10.1.5.1.6. Others 1.10.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 1.10.1.6.1.1. Hospitals 1.10.1.6.1.1.1. Pharmacies 1.11. Latin America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 2018-2026 1.11.1.1. Key Market Findings 1.11.1.2. Long Term ROI Segments 1.11.1.3. Revenue Opportunity Influencing Factors 1.11.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026 1.11.1.4.1.1. Brazil 1.11.1.4.1.2. Mexico 1.11.1.4.1.3. Argentina 1.11.1.4.1.4. Rest of Latin America 1.11.1.5. Market Revenue (USD Mn) Assessment and Forecast by Indication, 2018-2026 1.11.1.5.1.1. Lung Cancer 1.11.1.5.1.2. Breast Cancer 1.11.1.5.1.3. Prostate Cancer 1.11.1.5.1.4. Skin Cancer 1.11.1.5.1.5. Bladder Cancer 1.11.1.5.1.6. Others 1.11.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 1.11.1.6.1.1. Hospitals 1.11.1.6.1.1.1. Pharmacies 1.12. Europe America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 2018-2026 1.12.1.1. Key Market Findings 1.12.1.2. Long Term ROI Segments 1.12.1.3. Revenue Opportunity Influencing Factors 1.12.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026 1.12.1.4.1.1. Germany 1.12.1.4.1.2. France 1.12.1.4.1.3. Spain 1.12.1.4.1.4. UK 1.12.1.4.1.5. Russia 1.12.1.4.1.6. Poland 1.12.1.4.1.7. Rest of Europe 1.12.1.5. Market Revenue (USD Mn) Assessment and Forecast by Indication, 2018-2026 1.12.1.5.1.1. Lung Cancer 1.12.1.5.1.2. Breast Cancer 1.12.1.5.1.3. Prostate Cancer 1.12.1.5.1.4. Skin Cancer 1.12.1.5.1.5. Bladder Cancer 1.12.1.5.1.6. Others 1.12.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 1.12.1.6.1.1. Hospitals 1.12.1.6.1.1.1. Pharmacies 1.13. Asia Pacific America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 20182026 1.13.1.1. Key Market Findings 1.13.1.2. Long Term ROI Segments 1.13.1.3. Revenue Opportunity Influencing Factors 1.13.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026 1.13.1.4.1.1. Emerging Asia 1.13.1.4.1.1.1.1. China 1.13.1.4.1.1.1.2. India 1.13.1.4.1.1.1.3. ASEAN-5 1.13.1.4.1.1.1.4. Rest of Emerging Asia 1.13.1.4.1.2. Japan 1.13.1.5. Market Revenue (USD Mn) Assessment and Forecast by Indication, 2018-2026 1.13.1.5.1.1. Lung Cancer 1.13.1.5.1.2. Breast Cancer 1.13.1.5.1.3. Prostate Cancer 1.13.1.5.1.4. Skin Cancer 1.13.1.5.1.5. Bladder Cancer 1.13.1.5.1.6. Others 1.13.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 1.13.1.6.1.1. Hospitals 1.13.1.6.1.1.1. Pharmacies 1.14. Rest of World America Off-Label Anticancer Drugs Market Revenue (US$ Mn), 20182026 1.14.1.1. Key Market Findings 1.14.1.2. Long Term ROI Segments 1.14.1.3. Revenue Opportunity Influencing Factors 1.14.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026 1.14.1.4.1.1. Middle East 1.14.1.4.1.2. South Africa 1.14.1.4.1.3. North Africa 1.14.1.4.1.4. Rest of World 1.14.1.5. Market Revenue (USD Mn) Assessment and Forecast by Indication, 2018-2026 1.14.1.5.1.1. Lung Cancer 1.14.1.5.1.2. Breast Cancer 1.14.1.5.1.3. Prostate Cancer 1.14.1.5.1.4. Skin Cancer 1.14.1.5.1.5. Bladder Cancer 1.14.1.5.1.6. Others 1.14.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 1.14.1.6.1.1. Hospitals 1.14.1.6.1.1.1. Pharmacies 1.15. Company Profiles 1.15.1.1. Competition Landscape 1.15.1.2. Global Company Share (USD Mn) Overview, 2018 1.15.1.3. Company Profiles 1.15.1.3.1.1. Pfizer Inc 1.15.1.3.1.1.1.1. Corporate Overview 1.15.1.3.1.1.1.2. Financial Performance 1.15.1.3.1.1.1.3. Peer Comparison & 3C marketing equation 1.15.1.3.1.1.1.4. Company Strategy & Channel Management 1.15.1.3.1.2. Roche Holding 1.15.1.3.1.2.1.1. Corporate Overview 1.15.1.3.1.2.1.2. Financial Performance 1.15.1.3.1.2.1.3. Peer Comparison & 3C marketing equation 1.15.1.3.1.2.1.4. Company Strategy & Channel Management 1.15.1.3.1.3. Merck Co & Inc 1.15.1.3.1.3.1.1. Corporate Overview 1.15.1.3.1.3.1.2. Financial Performance 1.15.1.3.1.3.1.3. Peer Comparison & 3C marketing equation 1.15.1.3.1.3.1.4. Company Strategy & Channel Management 1.15.1.3.1.4. Novartis AG 1.15.1.3.1.4.1.1. Corporate Overview 1.15.1.3.1.4.1.2. Financial Performance 1.15.1.3.1.4.1.3. Peer Comparison & 3C marketing equation 1.15.1.3.1.4.1.4. Company Strategy & Channel Management 1.15.1.3.1.5. Sanofi S.A. 1.15.1.3.1.5.1.1. Corporate Overview 1.15.1.3.1.5.1.2. Financial Performance 1.15.1.3.1.5.1.3. Peer Comparison & 3C marketing equation 1.15.1.3.1.5.1.4. Company Strategy & Channel Management 1.16. Research Sources & Primary Verbatim Inquire further details about this report at: [email protected] About FutureWise Research: We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future. Contact Us: Company Name: FutureWise Research Contact Person: Vinay Thaploo Email: [email protected] Phone: +44 141 628 9353 / +1 970 279 4295 City: Leeds Country: United Kingdom Website: www.futurewiseresearch.com
Off label is the unwarranted or non-approved use of the drug. Under three conditions a drug is off-label. The conditions are • The measures needed to extend the consent were not made albeit implication of adequacy is applicable • The drug is ineffectual or ineffective • It falls in 'grey zone' information-based medicine in which top-level evidence of is tough to find even for the treatments which are fairly effective.
© Copyright 2024 Paperzz
